Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 218

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Clinical Value of RNA Sequencing–Based Classifiers for Prediction of the Five Conventional Breast Cancer Biomarkers: A Report From the Population-Based Multicenter Sweden Cancerome Analysis Network—Breast Initiative

Open access
Brueffer, Christian, Vallon-Christersson, Johan, Grabau, Dorthe, Ehinger, Anna, Häkkinen, Jari, Hegardt, Cecilia, Malina, Janne, Chen, Yilun, Bendahl, Pär-Ola, Manjer, Jonas, Malmberg, Martin, Larsson, Christer, Loman, Niklas, Rydén, Lisa, Borg, Åke, Saal, Lao H. · 2018 · JCO Precision Oncology

Abstract

Purpose: In early breast cancer (BC), five conventional biomarkers—estrogen receptor (ER), progesterone receptor (PgR), human epidermal growth factor receptor 2 (HER2), Ki67, and Nottingham histologic grade (NHG)—are used to determine prognosis and treatment. We aimed to develop classifiers for these biomarkers that were based on tumor mRNA sequencing (RNA-seq), compare classification performance, and test whether such predictors could add value for risk stratification. Methods: In total, 3,678 patients with BC were studied. For 405 tumors, a comprehensive multi-rater histopathologic evaluation was performed. Using RNA-seq data, single-gene classifiers and multigene classifiers (MGCs) were trained on consensus histopathology labels. Trained classifiers were tested on a prospective population-based series of 3,273 BCs that included a median follow-up of 52 months (Sweden Cancerome Analysis Network—Breast [SCAN-B], ClinicalTrials.gov identifier: NCT02306096), and results were evaluated by agreement statistics and Kaplan-Meier and Cox survival analyses. Results: Pathologist concordance was high for ER, PgR, and HER2 (average κ, 0.920, 0.891, and 0.899, respectively) but moderate for Ki67 and NHG (average κ, 0.734 and 0.581). Concordance between RNA-seq classifiers and histopathology for the independent cohort of 3,273 was similar to interpathologist concordance. Patients with discordant classifications, predicted as hormone responsive by histopathology but non–hormone responsive by MGC, had significantly inferior overall survival compared with patients who had concordant results. This extended to patients who received no adjuvant therapy (hazard ratio [HR], 3.19; 95% CI, 1.19 to 8.57), or endocrine therapy alone (HR, 2.64; 95% CI, 1.55 to 4.51). For cases identified as hormone responsive by histopathology and who received endocrine therapy alone, the MGC hormone-responsive classifier remained significant after multivariable adjustment (HR, 2.45; 95% CI, 1.39 to 4.34). Conclusion: Classification error rates for RNA-seq–based classifiers for the five key BC biomarkers generally were equivalent to conventional histopathology. However, RNA-seq classifiers provided added clinical value in particular for tumors determined by histopathology to be hormone responsive but by RNA-seq to be hormone insensitive.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/po.17.00135

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Research works printed but not linked: 32

  1. 10.6004/jnccn.2014.0058 · DOI · Paper page
  2. 10.1093/annonc/mdv298 · DOI · Paper page
  3. 10.1200/JCO.2009.25.6529 · DOI · Paper page
  4. 10.1158/1078-0432.CCR-05-0636 · DOI · Paper page
  5. 10.1200/JCO.2005.03.4744 · DOI · Paper page
  6. 10.1080/02841860902862511 · doi:10.1080/02841860902862511
  7. 10.3109/0284186X.2015.1037012 · doi:10.3109/0284186x.2015.1037012
  8. 10.1200/JCO.2013.50.9984 · DOI · Paper page
  9. 10.1093/jnci/djr393 · DOI · Paper page
  10. 10.1093/jnci/djt306 · DOI · Paper page
  11. 10.1159/000430488 · doi:10.1159/000430488
  12. 10.1186/bcr2607 · DOI · Paper page
  13. 10.1073/pnas.0702507104 · DOI · Paper page
  14. 10.1200/JCO.2008.18.1370 · DOI · Paper page
  15. 10.1158/1078-0432.CCR-09-0449 · DOI
  16. Häkkinen J, bioRxiv
  17. 10.1073/pnas.082099299 · DOI · Paper page
  18. Viera AJ, 2005, Fam Med, 37, 360
  19. 10.1371/journal.pone.0082144 · doi:10.1371/journal.pone.0082144
  20. 10.1093/hmg/ddg347 · DOI
  21. 10.1093/annonc/mdu026 · DOI
  22. 10.1007/s10549-014-3163-8 · DOI
  23. 10.1101/gr.189621.115 · DOI · Paper page
  24. 10.1126/scitranslmed.3003161 · DOI · Paper page
  25. 10.1056/NEJMoa1602253 · DOI · Paper page
  26. 10.1080/028418600430950 · DOI
  27. 10.1186/bcr2257 · DOI · Paper page
  28. 10.1038/srep38037 · DOI
  29. Dhondalay GK, 2011, Proc Int Conf Mach Learn Cybern, 2, 727
  30. 10.1056/NEJMoa041588 · DOI · Paper page
  31. 10.1158/0008-5472.CAN-05-4414 · DOI · Paper page
  32. 10.1093/jnci/djj052 · DOI · Paper page

Cited by

See all 218

Metadata

Authors
Brueffer, C., Vallon-Christersson, J., Grabau, D., Ehinger, A., Häkkinen, J., Hegardt, C., Malina, J., Chen, Y., Bendahl, P.-O., Manjer, J., Malmberg, M., Larsson, C., Loman, N., Rydén, L., Borg, Å., & Saal, L. H.
Venue
JCO Precision Oncology
Published
2018-11
Volume
2
Issue
2
Pages
1-18
ISSN
2473-4284 (ISSN-L)
OpenAlex
W2792135005
Cited by
218
References
6
FWCI
5.22
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical Value of RNA Sequencing–Based Classifiers for Prediction of the Five Conventional Breast Cancer Biomarkers: A Report From the Population-Based Multicenter Sweden Cancerome Analysis Network—Breast Initiative. https://app.cochat.ai/papers/10.1200/po.17.00135
The paper
Brueffer, C., Vallon-Christersson, J., Grabau, D., Ehinger, A., Häkkinen, J., Hegardt, C., Malina, J., Chen, Y., Bendahl, P.-O., Manjer, J., Malmberg, M., Larsson, C., Loman, N., Rydén, L., Borg, Å., & Saal, L. H. (2018). Clinical Value of RNA Sequencing–Based Classifiers for Prediction of the Five Conventional Breast Cancer Biomarkers: A Report From the Population-Based Multicenter Sweden Cancerome Analysis Network—Breast Initiative. JCO Precision Oncology. https://doi.org/10.1200/po.17.00135

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.